Trials / Completed
CompletedNCT00964028
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)
Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 60 Days – 90 Days
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infanrix™-IPV/Hib | Intramuscular, three doses |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-04-12
- Completion
- 2010-04-12
- First posted
- 2009-08-24
- Last updated
- 2018-06-06
- Results posted
- 2017-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00964028. Inclusion in this directory is not an endorsement.